{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=200+mg+emtricitabine+and+300+mg+tenofovir+disoproxil+fumarate&page=5", "query": { "intervention": "200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate", "page": 5 }, "page_size": 10 }, "pagination": { "page": 5, "page_size": 10, "total_count": 107, "total_pages": 11, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=200+mg+emtricitabine+and+300+mg+tenofovir+disoproxil+fumarate&page=6&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=200+mg+emtricitabine+and+300+mg+tenofovir+disoproxil+fumarate&page=4&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-14T17:39:32.224Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01106586", "title": "Study to Evaluate the Safety and Efficacy of Stribild Versus Ritonavir-Boosted Atazanavir Plus Truvada in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV", "HIV Infections" ], "interventions": [ { "name": "Stribild", "type": "DRUG" }, { "name": "ATV", "type": "DRUG" }, { "name": "Ritonavir", "type": "DRUG" }, { "name": "FTC/TDF", "type": "DRUG" }, { "name": "Stribild Placebo", "type": "DRUG" }, { "name": "ATV Placebo", "type": "DRUG" }, { "name": "RTV Placebo", "type": "DRUG" }, { "name": "FTC/TDF Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 708, "start_date": "2010-04", "completion_date": "2014-09", "has_results": true, "last_update_posted_date": "2015-11-11", "last_synced_at": "2026-10-14T17:39:32.224Z", "location_count": 86, "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 57 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Costa Mesa", "state": "California" }, { "city": "Denver", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01106586" }, { "nct_id": "NCT00117676", "title": "A Study to Compare Tenofovir Disoproxil Fumarate Versus Adefovir Dipivoxil for the Treatment of HBeAg-Negative Chronic Hepatitis B", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Hepatitis B" ], "interventions": [ { "name": "TDF", "type": "DRUG" }, { "name": "ADV", "type": "DRUG" }, { "name": "TDF placebo", "type": "DRUG" }, { "name": "ADV placebo", "type": "DRUG" }, { "name": "FTC/TDF", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "69 Years", "sex": "ALL", "summary": "18 Years to 69 Years" }, "enrollment_count": 382, "start_date": "2005-02", "completion_date": "2016-01", "has_results": true, "last_update_posted_date": "2017-03-07", "last_synced_at": "2026-10-14T17:39:32.224Z", "location_count": 17, "location_summary": "La Jolla, California • Pasadena, California • San Diego, California + 12 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Pasadena", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00117676" }, { "nct_id": "NCT02345252", "title": "Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Adults Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV-1 Infection" ], "interventions": [ { "name": "FTC/RPV/TAF", "type": "DRUG" }, { "name": "FTC/RPV/TDF Placebo", "type": "DRUG" }, { "name": "FTC/RPV/TDF", "type": "DRUG" }, { "name": "FTC/RPV/TAF Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 632, "start_date": "2015-01-26", "completion_date": "2019-01-09", "has_results": true, "last_update_posted_date": "2020-01-02", "last_synced_at": "2026-10-14T17:39:32.224Z", "location_count": 75, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 56 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Long Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02345252" }, { "nct_id": "NCT06511063", "title": "Antiviral Clinical Trial for Long Covid-19", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Long Covid" ], "interventions": [ { "name": "tenofovir disoproxil/emtricitabine", "type": "DRUG" }, { "name": "Selzentry", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Icahn School of Medicine at Mount Sinai", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 90, "start_date": "2024-10-01", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2026-03-13", "last_synced_at": "2026-10-14T17:39:32.224Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06511063" }, { "nct_id": "NCT01293123", "title": "Raltegravir Cerebrospinal Fluid Pharmacodynamic Study in HIV-Infected Individuals", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "HIV" ], "interventions": [ { "name": "Raltegravir", "type": "DRUG" }, { "name": "Efavirenz", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Diego", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 2, "start_date": "2011-12", "completion_date": "2013-12", "has_results": true, "last_update_posted_date": "2019-10-31", "last_synced_at": "2026-10-14T17:39:32.224Z", "location_count": 1, "location_summary": "San Diego, California", "locations": [ { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01293123" }, { "nct_id": "NCT04644029", "title": "Oral ISL QM as PrEP in Cisgender Women at High Risk for HIV-1 Infection (MK-8591-022)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV-I", "Human Immunodeficiency Virus Type 1", "Prophylaxis" ], "interventions": [ { "name": "Islatravir", "type": "DRUG" }, { "name": "Placebo to FTC/TDF", "type": "DRUG" }, { "name": "FTC/TDF", "type": "DRUG" }, { "name": "Placebo to ISL", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "16 Years", "maximum_age": "45 Years", "sex": "FEMALE", "summary": "16 Years to 45 Years · Female only" }, "enrollment_count": 730, "start_date": "2021-02-24", "completion_date": "2024-06-11", "has_results": true, "last_update_posted_date": "2026-02-04", "last_synced_at": "2026-10-14T17:39:32.224Z", "location_count": 13, "location_summary": "Birmingham, Alabama • Washington D.C., District of Columbia • Miami, Florida + 10 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Miami", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04644029" }, { "nct_id": "NCT00677300", "title": "Raltegravir And Darunavir Antiretroviral in Antiretroviral Naive Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Raltegravir", "type": "DRUG" }, { "name": "Darunavir", "type": "DRUG" }, { "name": "Ritonavir", "type": "DRUG" }, { "name": "Tenofovir/Emtricitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dallas VA Medical Center", "sponsor_class": "FED", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 85, "start_date": "2009-01", "completion_date": "2012-12", "has_results": false, "last_update_posted_date": "2014-09-08", "last_synced_at": "2026-10-14T17:39:32.224Z", "location_count": 2, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00677300" }, { "nct_id": "NCT05457530", "title": "Doravirine and Weight Gain in Antiretroviral Naive", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Body Weight Changes", "Human Immunodeficiency Virus", "ART", "Obesity", "Minority Health", "BMD", "Metabolic Syndrome", "Fasting" ], "interventions": [ { "name": "DOR/3TC/TDF", "type": "DRUG" }, { "name": "DOR + FTC/TAF", "type": "COMBINATION_PRODUCT" }, { "name": "BIC/FTC/TAF", "type": "DRUG" } ], "intervention_types": [ "DRUG", "COMBINATION_PRODUCT" ], "sponsor": "Prism Health North Texas", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 0, "start_date": "2022-08-01", "completion_date": "2023-05-03", "has_results": false, "last_update_posted_date": "2023-05-12", "last_synced_at": "2026-10-14T17:39:32.224Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05457530" }, { "nct_id": "NCT02603107", "title": "Study to Evaluate the Safety and Efficacy of Switching From Regimens Consisting of Boosted Atazanavir or Darunavir Plus Either Emtricitabine/Tenofovir or Abacavir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV-1 Infection" ], "interventions": [ { "name": "RTV", "type": "DRUG" }, { "name": "ATV", "type": "DRUG" }, { "name": "DRV", "type": "DRUG" }, { "name": "COBI", "type": "DRUG" }, { "name": "ATV/co", "type": "DRUG" }, { "name": "DRV/co", "type": "DRUG" }, { "name": "FTC/TDF", "type": "DRUG" }, { "name": "ABC/3TC", "type": "DRUG" }, { "name": "B/F/TAF", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 578, "start_date": "2015-11-20", "completion_date": "2019-12-23", "has_results": true, "last_update_posted_date": "2020-12-29", "last_synced_at": "2026-10-14T17:39:32.224Z", "location_count": 63, "location_summary": "Phoenix, Arizona • Los Angeles, California • Newport Beach, California + 49 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02603107" }, { "nct_id": "NCT00775606", "title": "Immune Reconstitution of Lopinavir/Ritonavir-Based vs Efavirenz-based HAART in Advanced HIV Disease", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Acquired Immune Deficiency Syndrome" ], "interventions": [ { "name": "Lopinavir 400 mg/ritonavir 100 mg", "type": "DRUG" }, { "name": "Efavirenz", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Rush University Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 15, "start_date": "2008-10", "completion_date": "2011-01", "has_results": true, "last_update_posted_date": "2023-05-26", "last_synced_at": "2026-10-14T17:39:32.224Z", "location_count": 4, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00775606" } ] }